Home / Featured

ctDNA and Minimal Residual Disease

Circulating tumour DNA as a decision-making tool: tumour-informed versus tissue-free assays, minimal residual disease after surgery, and whether a molecular relapse signal should change what treatment a patient receives.

3 articles in this topic

  • October 2, 2026Nature MedicineuRARE-seq (non-randomized biomarker study)

    Urine Cell-Free RNA Test Detects Bladder Cancer at 95% Sensitivity and 90% Specificity, but Residual-Disease and BCG-Response Findings Rest on Small Cohorts

    uRARE-seq is a tumor-naive urine cell-free RNA (cfRNA) sequencing approach, applied to 683 urine samples from patients with cancer and controls. In the training cohort (100 controls, 151 bladder cancer samples), the detection model reached an AUC of 0.97, with a sensitivity of 95% at 90% specificity.

  • August 13, 2026JAMA Oncologyc-TRAK TN (NCT03145961)

    Tissue-Free ctDNA Testing Matches Tumor-Informed Assays for Detecting TNBC Recurrence

    In a prognostic analysis nested within the phase 2 c-TRAK TN trial, a tissue-free ctDNA assay detected molecular residual disease in 54 of 159 patients (34.0%) with early triple negative breast cancer, and detection was strongly associated with recurrence risk (HR, 27.2).

  • July 3, 2026JAMA OncologyCIRCULATE-Japan GALAXY (UMIN000039205)

    ctDNA-Guided MRD Status Predicts Who Benefits From Chemo After Liver Metastasis Surgery

    Retrospective subset analysis of the CIRCULATE-Japan GALAXY registry (298 patients with resected colorectal liver metastases) testing whether ctDNA-defined molecular residual disease (MRD) status can identify who actually benefits from adjuvant chemotherapy (ACT) after liver resection

Cancer types covered: Bladder Cancer · Breast Cancer · Colorectal Cancer